DOYLE THOMAS JAMES
SEC CIK 1910331 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KURA | Kura Oncology, Inc. | SVP, Fin, Accounting | 150.1K | — | $253.5K | 13 | 2022-02-07 | 2026-01-27 |
Most active insiders at KURA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | WILSON TROY EDWARD | Pres, CEO, Dir | $2.35M | $327.3K |
| 2 | Leoni Mollie | Chief Medical Off | — | $1.19M |
| 3 | Bair Teresa Brophy | CLO | — | $690.8K |
| 4 | Burrows Francis | CSO | — | $467.6K |
| 5 | Powl Brian T. | Chief Commercial Off | — | $397.9K |
| 6 | FORD KATHLEEN | COO | — | $174.6K |
| 7 | DOYLE THOMAS JAMES | SVP, Fin, Accounting | — | $151.8K |
| 8 | Hasnain Faheem | Dir | — | $109.8K |
| 9 | Malley Thomas | Dir | — | — |
Transactions 13
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-01-27 | 2026-01-27 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | S - Sale | $8.46 | -7,142 | 150.1K | -5% | -$60.4K |
| D | 2026-01-06 | 2026-01-02 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | A - Grant | $0.00 | +21.2K | 152.3K | +16% | $0 |
| 2025-11-14 | 2025-11-14 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | S - Sale | $11.18 | -4,539 | 130.3K | -3% | -$50.7K | |
| 2025-11-14 | 2025-11-13 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | A - Grant | $0.00 | +25.0K | 134.8K | +23% | $0 | |
| 2025-09-29 | 2025-09-27 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | A - Grant | $0.00 | +25.0K | 114.4K | +28% | $0 | |
| 2025-09-29 | 2025-09-29 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | S - Sale | $8.94 | -4,541 | 109.8K | -4% | -$40.6K | |
| M | 2025-01-28 | 2025-01-28 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | S - Sale | $7.87 | -4,949 | 88.2K | -5% | -$38.9K |
| DM | 2025-01-06 | 2025-01-02 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | A - Grant | $0.00 | +42.5K | 93.1K | +84% | $0 |
| M | 2024-01-31 | 2024-01-29 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | S - Sale | $17.80 | -2,318 | 48.1K | -5% | -$41.3K |
| D | 2024-01-04 | 2024-01-02 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | A - Grant | $0.00 | +21.2K | 50.4K | +73% | $0 |
| D | 2023-02-21 | 2023-02-16 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | A - Grant | $0.00 | +10.6K | 27.5K | +63% | $0 |
| M | 2023-01-31 | 2023-01-27 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | S - Sale | $13.89 | -1,548 | 17.7K | -8% | -$21.5K |
| D | 2022-02-09 | 2022-02-07 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | SVP, Fin, Accounting | A - Grant | $0.00 | +8,390 | 15.0K | +127% | $0 |
Purchase Sale Sale after option exercise All abbreviations